PFKFB3通过组蛋白乳酰化激活NF-κB家族驱动肾脏纤维化
研究揭示糖酵解酶PFKFB3在小鼠缺血再灌注损伤及多种病因CKD患者的肾近端小管细胞中显著诱导,且与纤维化严重程度正相关。PFKFB3介导的乳酸生成增强组蛋白H4K12la乳酰化,富集于NF-κB信号基因启动子,激活炎症反应。靶向PFKFB3-NF-κB通路可能成为CKD治疗新策略。
要点
- PFKFB3在CKD近端小管细胞中诱导,与纤维化严重程度正相关。
- PFKFB3缺失或抑制可减轻小鼠肾脏炎症和纤维化,保护肾功能。
- 乳酸-H4K12la-NF-κB轴介导PFKFB3促纤维化效应,是潜在治疗靶点。
核心结论
- 肾小管PFKFB3通过促进H4K12la介导的NF-κB信号基因转录及激活,双重增强NF-κB信号,驱动肾脏炎症和纤维化。
研究设计与样本
- 研究采用小鼠缺血再灌注损伤模型及多种病因CKD患者样本,结合近端小管细胞特异性基因敲除、杂合缺陷及PFKFB3抑制剂干预。
主要发现
- 小鼠IRI后及多种病因CKD患者近端小管细胞中PFKFB3表达显著诱导,且与肾脏纤维化严重程度正相关。
- CKD患者尿乳酸/肌酐水平及小鼠肾脏乳酸水平升高。
- 近端小管细胞特异性敲除PFKFB3显著降低肾脏乳酸水平,减轻炎症和纤维化,并保护肾功能。
- PFKFB3杂合缺陷或抑制剂处理小鼠观察到类似保护效应。
- PFKFB3介导的乳酸增强组蛋白H4K12la乳酰化,富集于Ikbkb、Rela、Relb启动子,激活转录;PFKFB3敲除抑制IRI肾脏中IKKβ、IκBα和p65活化。
关键数值与推荐
- CKD患者中H4K12la水平升高与肾脏炎症和纤维化正相关。
临床怎么用
- 靶向肾小管细胞PFKFB3介导的NF-κB信号通路可能成为CKD治疗新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Persistently elevated glycolysis in kidney has been demonstrated to promote chronic kidney disease (CKD). However, the underlying mechanism remains largely unclear. Here, we observed that 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), a key glycolytic enzyme, was remarkably induced in kidney proximal tubular cells (PTCs) following ischemia-reperfusion injury (IRI) in mice, as well as in multiple etiologies of patients with CKD. PFKFB3 expression was positively correlated with the severity of kidney fibrosis. Moreover, patients with CKD and mice exhibited increased urinary lactate/creatine levels and kidney lactate, respectively. PTC-specific deletion of PFKFB3 significantly reduced kidney lactate levels, mitigated inflammation and fibrosis, and preserved kidney function in the IRI mouse model. Similar protective effects were observed in mice with heterozygous deficiency of PFKFB3 or those treated with a PFKFB3 inhibitor. Mechanistically, lactate derived from PFKFB3-mediated tubular glycolytic reprogramming markedly enhanced histone lactylation, particularly H4K12la, which was enriched at the promoter of NF-κB signaling genes like Ikbkb, Rela, and Relb, activating their transcription and facilitating the inflammatory response. Further, PTC-specific deletion of PFKFB3 inhibited the activation of IKKβ, I κ B α, and p65 in the IRI kidneys. Moreover, increased H4K12la levels were positively correlated with kidney inflammation and fibrosis in patients with CKD. These findings suggest that tubular PFKFB3 may play a dual role in enhancing NF-κB signaling by promoting both H4K12la-mediated gene transcription and its activation. Thus, targeting the PFKFB3-mediated NF-κB signaling pathway in kidney tubular cells could be a novel strategy for CKD therapy.
引用
- Wang Y, Li H, Jiang S, et al. The glycolytic enzyme PFKFB3 drives kidney fibrosis through promoting histone lactylation-mediated NF-κB family activation. Kidney Int. 2024. PMID: 38789037. doi:10.1016/j.kint.2024.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。